NCT05990725View on ClinicalTrials.gov

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2025

Conditions
Atopic DermatitisEczema
Interventions
BIOLOGICAL

Lebrikizumab

Lebrikizumab solution for injection administered subcutaneously.

Trial Locations (33)

Unknown

Site 34, Augsburg

Site 9, Berlin

Site 29, Bonn

Site 27, Dresden

Site 28, Düsseldorf

Site 11, Erlangen

Site 37, Frankfurt

Site 32, Freiburg im Breisgau

Site 5, Göttingen

Site 15, Hamburg

Site 3, Hamburg

Site 8, Hamburg

Site 23, Heidelberg

Site 1, Kiel

Site 19, Langenau

Site 10, Lübeck

Site 26, Mainz

Site 6, Mannheim

Site 36, Marburg

Site 13, München

Site 17, München

Site 33, München

Site 4, Münster

Site 12, Oberhausen

Site 22, Oldenburg

Site 2, Potsdam

Site 30, Regensburg

Site 7, Rostock

Site 18, Tübingen

Site 35, Bergen op Zoom

Site 41, Utrecht

Site 38, Leeds

Site 14, York

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT05990725 - Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter